Core Insights - Junshi Biosciences (01877) reported a revenue of 1.806 billion RMB for the first three quarters of 2025, representing a year-on-year growth of 42.06% [1] - The net loss attributable to shareholders narrowed to 596 million RMB, a decrease of 35.7% compared to the previous year [1] - The basic loss per share was 0.60 RMB [1] Revenue Growth - The increase in revenue was primarily driven by the sales of commercialized drugs, with the core product Toripalimab injection (brand name: Tuoyi/LOQTORZI, product code: JS001) generating approximately 1.495 billion RMB in sales in the domestic market, reflecting a year-on-year growth of about 40% [1] Cost Management - The company is implementing a "quality improvement and efficiency enhancement" action plan, focusing on cost control and resource allocation, which has significantly reduced the loss amount compared to the same period last year [1] Financial Position - As of the end of the reporting period, the company had a total balance of cash and trading financial assets amounting to 3.270 billion RMB, indicating a strong liquidity position [1]

Core Insights - The company reported a revenue of 1.806 billion RMB for the first three quarters of 2025, representing a year-on-year growth of 42.06% [1] - The net loss attributable to shareholders narrowed to 596 million RMB, a decrease of 35.7% compared to the previous year [1] - The basic loss per share was 0.60 RMB [1] Revenue Growth - The increase in revenue was primarily driven by the sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi®/LOQTORZI®), which generated approximately 1.495 billion RMB in sales in the domestic market, reflecting a year-on-year growth of about 40% [1] Cost Management and Financial Position - The company has implemented a "quality improvement and efficiency enhancement" action plan, focusing on cost control and resource allocation, which has significantly reduced the loss amount compared to the same period last year [1] - As of the end of the reporting period, the company had a total balance of cash and trading financial assets amounting to 3.270 billion RMB, indicating a strong liquidity position [1]

Core Insights - Junshi Biosciences (01877.HK) reported a revenue of approximately RMB 637 million for Q3 2025, representing a year-on-year increase of 31.4% [1] - The company recorded a net loss of approximately RMB 183 million, with a basic earnings per share of -0.18 yuan [1] - For the first three quarters, the revenue was approximately RMB 1.805 billion, reflecting a year-on-year growth of 42.06% [1] - The net loss for the first three quarters amounted to RMB 596 million [1]

Financial Performance - The company's revenue for the third quarter reached ¥637,496,183.86, representing a year-on-year increase of 31.40%[9] - The total profit for the quarter was a loss of ¥207,181,531.29, with a cumulative loss of ¥692,393,121.41 for the year-to-date[9] - The net profit attributable to shareholders was a loss of ¥183,004,561.78 for the quarter, with a year-to-date loss of ¥595,700,160.22[9] - The basic and diluted earnings per share for the quarter were both -¥0.18, with a year-to-date figure of -¥0.60[9] - The net loss for the first three quarters of 2025 was ¥674,309,869.11, compared to a net loss of ¥988,725,690.94 in the same period of 2024, showing an improvement of about 31.8%[26] - The company reported a basic and diluted earnings per share of -¥0.60 for the first three quarters of 2025, an improvement from -¥0.94 in the same period of 2024[27] Research and Development - Research and development expenses totaled ¥276,576,934.80, accounting for 43.38% of the revenue, a decrease of 24.21 percentage points compared to the previous year[10] - Research and development expenses for the first three quarters of 2025 amounted to ¥982,154,685.41, up from ¥874,268,925.53 in 2024, reflecting a growth of approximately 12.3%[26] - The company plans to accelerate the research and development of its pipeline and enhance its commercial competitiveness to drive future revenue growth[20] Assets and Liabilities - Total assets increased to ¥11,688,041,635.35, reflecting an 8.40% increase from the end of the previous year[10] - The total assets as of September 30, 2025, were ¥11,688,041,635.35, an increase from ¥10,781,960,410.10 at the end of 2024, representing a growth of approximately 8.4%[23] - Total liabilities as of September 30, 2025, were ¥5,392,722,223.47, compared to ¥4,849,830,645.95 at the end of 2024, indicating an increase of about 11.2%[23] Cash Flow - The company reported a net cash flow from operating activities of -¥343,410,268.17 for the year-to-date[9] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 2,139,612,068.29, a 53.1% increase compared to CNY 1,396,882,602.67 in the same period of 2024[28] - The net cash flow from operating activities improved to -CNY 343,410,268.17 in 2025, compared to -CNY 1,113,472,084.61 in 2024, indicating a significant reduction in losses[28] - Cash inflow from investment activities totaled CNY 1,718,649,206.70, up from CNY 941,248,272.00 in 2024, marking an increase of 82.7%[29] - The net cash flow from investment activities was -CNY 908,789,645.64 in 2025, an improvement from -CNY 1,083,510,749.67 in 2024[29] - Cash inflow from financing activities reached CNY 3,533,008,134.16, compared to CNY 1,933,431,848.11 in the previous year, reflecting an increase of 82.6%[29] - The net cash flow from financing activities was CNY 1,542,571,317.86, up from CNY 900,030,196.23 in 2024, showing a strong improvement[29] Shareholder Information - The total number of common shareholders at the end of the reporting period was 35,887, with 35,877 A-share common shareholders and 10 H-share common shareholders[17] - The top 10 shareholders hold a total of 260,291,110 shares, representing 25.35% of the total shares[16] Product Performance - The core product, Toripalimab injection (brand name: Tuoyi®/LOQTORZI®), achieved sales revenue of approximately CNY 1.495 billion, representing a year-on-year growth of about 40%[18] - The company has received approvals for 12 indications of Toripalimab in mainland China, with 10 of them included in the national medical insurance catalog[19] - The dual-specific antibody (code: JS207) for non-small cell lung cancer has received FDA approval for a Phase II/III clinical trial application[19] - The application for a new indication of Tuoyi® for first-line treatment of HER2-expressing urothelial carcinoma has been accepted by the National Medical Products Administration[19] Financial Position - The company's cash and cash equivalents, along with trading financial assets, totaled CNY 3.27 billion, indicating a strong liquidity position[18] - The company's cash and cash equivalents increased to ¥2,769,693,779.60 as of September 30, 2025, from ¥2,502,201,285.66 at the end of 2024, reflecting a growth of approximately 10.7%[22] - The total equity attributable to shareholders increased to ¥6,216,157,386.49 as of September 30, 2025, compared to ¥5,860,424,336.29 at the end of 2024, representing a growth of about 6.1%[23] - The company's long-term investments increased to ¥359,926,356.80 as of September 30, 2025, compared to ¥223,334,442.32 at the end of 2024, indicating a growth of approximately 61%[22] Operational Management - The company is focused on improving operational management to enhance its self-sustaining capabilities[20] - The company attributed the increase in revenue to the growth in sales of commercialized pharmaceuticals and improved cost management strategies[13] - The company received significant technical licensing fees during the year, contributing to the financial performance[13] Capital Expenditures - The cash outflow for purchasing fixed assets and other long-term assets was CNY 509,553,908.28, down from CNY 620,759,009.17 in 2024, indicating a reduction in capital expenditures[29] Accounting Standards - The company did not apply new accounting standards for the current reporting period[30]

Core Insights - Junshi Biosciences (688180.SH/1877.HK) reported a continuous increase in commercial revenue and accelerated R&D of differentiated innovative pipelines, showcasing improved sustainable operational capabilities [1][2]. Financial Performance - For the first three quarters, Junshi Biosciences achieved operating revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while narrowing its net loss to 596 million yuan, a reduction of 35.72% [1]. - In Q3 alone, the company recorded operating revenue of 637 million yuan, reflecting a year-on-year growth of 31.40% [2]. Product Performance - The core product, Tuoyi® (Tremelimumab), generated sales of 1.495 billion yuan in the first three quarters, marking a 40% year-on-year increase [2]. - Tuoyi® has seen six consecutive quarters of sequential growth since 2024, driven by enhanced sales efficiency and the inclusion of more indications in medical insurance [2]. Global Expansion - As of the end of Q3, Tuoyi® has been approved for marketing in over 40 countries and regions across four continents, including major markets like the U.S. and EU, with ongoing expansion into emerging regions [2][6]. - The global commercialization network has been established through partnerships with companies like Coherus and Dr. Reddy's, covering over 80 countries [2][6]. R&D and Pipeline Development - Junshi Biosciences is focusing on next-generation therapies, with high-potential pipelines such as JS207 (PD-1/VEGF), JS212 (HER3/EGFR dual antibody ADC), and JS015 (DKK1 monoclonal antibody) advancing rapidly [2][8]. - The company has developed over 50 drug candidates, including four commercialized products and nearly 30 in clinical stages, indicating strong product iteration capabilities [8]. Clinical Achievements - At the recent ESMO conference, Tuoyi® was highlighted for its combination therapy with ADC drug Vadisizumab, achieving significant clinical results, including an overall survival extension to 31.5 months compared to traditional chemotherapy [5][6]. - The company has also received positive results from its ongoing studies, including the registration study for JS005 (anti-IL-17A monoclonal antibody) in treating moderate to severe plaque psoriasis, which is expected to lead to a market application [11]. Strategic Initiatives - In September 2025, Junshi Biosciences launched an equity incentive plan with performance targets, reflecting strong confidence in future performance [3]. - The company is actively exploring combination therapies for its products, enhancing its competitive edge in the oncology market [9][10].

Core Insights - Junshi Biosciences reported a revenue of 637 million yuan for Q3 2025, marking a year-on-year increase of 31.4% [2] - The net profit attributable to shareholders for Q3 2025 was a loss of 183 million yuan [2] - For the first three quarters of 2025, the company achieved a total revenue of 1.806 billion yuan, reflecting a year-on-year growth of 42.06% [2] - The net profit attributable to shareholders for the first three quarters was a loss of 596 million yuan [2]

Core Viewpoint - Junshi Biosciences (688180.SH) reported a significant increase in revenue for Q3 2025, but still faced a net loss attributed to shareholders [1] Financial Performance - The company's operating revenue reached 637 million yuan, representing a year-on-year increase of 31.40% [1] - The net profit attributable to shareholders was -183 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -191 million yuan [1]

上海君实生物医药科技股份有限公司2025 年第三季度报告 证券代码：688180 证券简称：君实生物 上海君实生物医药科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | | | | | 动幅度（%） | | 增减变动幅度 | | | | | | （%） | | 营业收入 | 637,496,183.86 | 31.40 | ...

格隆汇10月28日｜君实生物(688180.SH)公告称，公司发布2025年第三季度报告，前三季度实现营业收 入18.06亿元，同比增长42.06%；归属于上市公司股东的净利润亏损5.96亿元。第三季度实现营业收入 6.37亿元，同比增长31.40%；归属于上市公司股东的净利润亏损1.83亿元。 ...

Core Insights - The company reported a revenue of 637 million yuan for Q3 2025, representing a year-on-year growth of 31.40% [1] - The net loss attributable to shareholders for the same quarter was 183 million yuan, with a basic earnings per share of -0.18 yuan [1] - For the first three quarters of 2025, the company achieved a total revenue of 1.806 billion yuan, marking a year-on-year increase of 42.06% [1] - The net loss attributable to shareholders for the first three quarters was 596 million yuan, with a basic earnings per share of -0.6 yuan [1]